Dr. Philipp Hoffmann is currently Senior Director Business Development & Licensing and leads a small BD team at Daiichi Sankyo Europe. His focus is the global search and evaluation of biologicals for the EU market, mostly in the field on oncology. Dr. Hoffmann received a degree in biology from the University of Göttingen. A scholarship from the University of California San Diego enabled him to work at the Scripps Research Institute. At Scripps he laid the technical foundation in the field of recombinant antibodies for his following PhD work performed at the University of Hamburg, which was supported by a grant from the Deutsche Krebshilfe. He entered the biotech industry in 2000 by joining the start-up Xerion Pharmaceuticals as a Staff Scientist. The subsequent engagement with MorphoSys, firstly as a Team Leader later as an Alliance Manager, led to his transition from Research to the commercial aspects of Product Development. Several partnerships with Big Pharma from EU, US and Japan were managed by Dr. Hoffmann. At Daiichi Sankyo he has been involved in several licensing agreements with biotech companies and the evaluation which led to the acquisition of Plexxikon. One of his priorities are commercial evaluations of biosimilars for the EU market.